


Author's Accepted Manuscript

Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis

Tessa Eagle, Fiona Stuart, Alicia S. Chua, Allison LaRussa, Kaitlynne Leclaire, Sandra L. Cook, Tanuja Chitnis, Howard L. Weiner, Bonnie I. Glanz, Brian C. Healy



PII: S2211-0348(17)30248-1
DOI: <https://doi.org/10.1016/j.msard.2017.10.002>
Reference: MSARD674

To appear in: *Multiple Sclerosis and Related Disorders*

Received date: 8 June 2017
Revised date: 31 August 2017
Accepted date: 4 October 2017

Cite this article as: Tessa Eagle, Fiona Stuart, Alicia S. Chua, Allison LaRussa, Kaitlynne Leclaire, Sandra L. Cook, Tanuja Chitnis, Howard L. Weiner, Bonnie I. Glanz and Brian C. Healy, Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis, *Multiple Sclerosis and Related Disorders*, <https://doi.org/10.1016/j.msard.2017.10.002>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies
for multiple sclerosis**

Tessa Eagle¹, Fiona Stuart¹, Alicia S. Chua¹, Allison LaRussa¹, Kaitlynne LeClaire¹, Sandra L. Cook¹,
Tanuja Chitnis^{1,2}, Howard L. Weiner^{1,2}, Bonnie I. Glanz^{1,2}, Brian C. Healy^{1,2,3*}

¹Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA

²Department of Neurology, Harvard Medical School, Boston, MA, USA

³Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA

*Correspondence to: Partners MS Center, 60 Fenwood Rd., 09002O, Boston, MA 02115, USA.

Telephone: 617-732-5376; Fax: 617-525-6571. bchealy@partners.org

Abstract

Background:

The recent approval of oral disease-modifying therapies (DMTs) for multiple sclerosis (MS) has provided patients with a new route of therapy administration. Little research has compared patients' experiences with and perceptions of injectable, infusion and oral MS therapies.

Methods:

Three hundred fifty-seven treated MS patients enrolled in the CLIMB study completed the Treatment Satisfaction Questionnaire for Medication (TSQM). The TSQM provides information regarding perceived effectiveness, side effects, convenience and overall satisfaction. The patients were treated with either interferon beta-1a intramuscular (IFN β -1a IM) (n = 40), interferon beta-1a subcutaneous (IFN β -1a SC) (n = 45), glatiramer acetate (GA) (n = 118), natalizumab (NTZ) (n = 44), fingolimod (n = 66), or dimethyl fumarate (BG-12) (n = 44). Multivariable linear regression models were used to compare treatment satisfaction across all DMTs and between patients treated with injectable (n = 203), infusion (n = 44), and oral (n = 110) DMTs. All models were adjusted for race, sex, age, disease duration, and disease category.

Results:

Patients taking oral DMTs reported significantly higher convenience scores compared to patients taking either injectable or infusion DMTs. The adjusted difference in the mean overall convenience score was

Download English Version:

<https://daneshyari.com/en/article/8647656>

Download Persian Version:

<https://daneshyari.com/article/8647656>

[Daneshyari.com](https://daneshyari.com)